Better Buy: Invitae vs. Illumina
Illumina (NASDAQ: ILMN) and Invitae (NYSE: NVTA) are two exciting genetic testing companies at dramatically different phases of the corporate lifecycle. For investors seeking a balanced biotech portfolio, there's a lot to appreciate about each of these companies, both of which look to have bright futures. But which company is the better buy for long-term growth?
As the biotech industry's premiere manufacturer of genetic sequencing hardware and molecular biology reagent kits, Illumina powers drug development and clinical genomics alike. Between acquiring the cloud genomics analysis company BlueBee and receiving emergency use authorization from the U.S. Food and Drug Administration (FDA) for its COVID-19 diagnostic test -- both of which happened in June -- Illumina is capitalizing on the pandemic rather than being slowed down by it. But there are a few factors that suggest Illumina's stock price will face some headwinds as it grows.
Image source: Getty Images.
Source Fool.com
